PMA device
Passive Plus, Isoflex S&p, and Isoflex Optim Leads
Abbott Medical · Permanent Defibrillator Electrodes (NVY, Class III) · First FDA decision May 16, 2008, newest Aug 13, 2015Ventricular arrhythmia and sudden cardiac arrest
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
0
Naming "Passive Plus Isoflex"
MAUDE reports
0
Brand "Passive Plus Isoflex", since 2015
PubMed studies
0
Mentioning "Passive Plus Isoflex"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Passive Plus, Isoflex S&p, and Isoflex Optim Leads
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- PASSIVE PLUS, ISOFLEX S&P, AND ISOFLEX OPTIM LEADSPMA supplement
P960030-S031 · Decided Aug 13, 2015 · 1,911 days after receipt · Normal 180 Day Track
Device type: Permanent defibrillator electrodes (NVY) · Cardiology
- PASSIVE PLUS, ISOFLEX S&P, AND ISOFLEX OPTIM LEADSPMA supplement
P960030-S032 · Decided Jul 25, 2011 · 343 days after receipt · Normal 180 Day Track No User Fee
Device type: Permanent defibrillator electrodes (NVY) · Cardiology
- PASSIVE PLUS/ISOFLEX S/P/OPTIMPMA supplement
P960030-S028 · Decided May 11, 2011 · 532 days after receipt · Normal 180 Day Track No User Fee
Device type: Permanent defibrillator electrodes (NVY) · Cardiology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Passive Plus Isoflex", any status and sponsor, newest update first.
No registered device study names "Passive Plus Isoflex".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Passive Plus Isoflex", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NVY
107,231 reports: 45,328 malfunction, 59,528 injury, 2,263 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Passive Plus Isoflex"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code NVY.
- Sprint Quattro Secure MRI SureScan Model 6947M leadMedtronic, Inc. · PMA 2022
- Attain Starfix LeadMedtronic, Inc. · PMA 2014
- Capsurefix Novus MRI Surescan Lead Model 5076Medtronic, Inc. · PMA 2016
- OmniaSecure MRI SureScan Lead Model 3930MMedtronic, Inc. · PMA 2026
- Medtronic(R) Transvene Lead SystemMedtronic, Inc. · PMA 2020
- Selectsecure LeadMedtronic Cardiac Rhythm Disease Management · PMA 2016
- Medtronic 4195 Attain Starfix Model 4195 LV LeadMedtronic, Inc. · PMA 2014
- Capsure Epicardial Pacing LeadMedtronic, Inc. · PMA 2013
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.